DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) announced participation in a fireside chat at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, from 2:30 PM to 3:00 PM EST. Key executives including CEO James E. Brown and CFO Michael H. Arenberg will present. The company's lead drug candidate, DUR-928, is in Phase 2b clinical trials for alcohol-associated hepatitis and has received FDA Fast Track Designation. POSIMIR, a non-opioid analgesic, is FDA-approved. Management will also hold virtual one-on-one meetings during the event.

Positive

• DUR-928 is in Phase 2b trials for alcohol-associated hepatitis and has received FDA Fast Track Designation.
• POSIMIR is FDA-approved, expanding the product portfolio.

Negative

• Ongoing clinical trials may face delays due to COVID-19 or other factors.
• There are risks that clinical trials may not confirm previous results or demonstrate efficacy.

CUPERTINO, Calif., Oct. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright.

Presentation details are as follows:

H.C. Wainwright 5th Annual NASH Investor Conference
Date:	October 12, 2021
Time:	2:30 P.M. to 3:00 P.M. Eastern Standard Time
Format:	Fireside chat hosted by Ed Arce
Webcast:	https://journey.ct.events/view/e01e1eb9-d8bf-4aad-be8d-e9f9a4914089

The webcast link of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

Management will also be available for virtual 1x1 meetings during the conference. If attendees would like to request a meeting, please contact H.C. Wainwright directly.

About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the Company's lead drug candidate, is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation. The Company is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, evaluating DUR-928's life saving potential compared to the current standard of care in patients with severe AH. Non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR^® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is now FDA-approved. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at www.posimir.com.  For more information about DURECT, please visit www.durect.com and follow us on Twitter  https://twitter.com/DURECTCorp.

DURECT Forward-Looking Statement
The statements in this press release regarding the potential for DUR-928 to treat patients with AH, NASH, and other diseases, multiple acute organ injury, ongoing and planned clinical trials of DUR-928, and the commercial potential of POSIMIR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of DUR-928, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life-saving potential of DUR-928 in a statistically significant manner, risks that we or a third-party licensee may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on July 30, 2021 under the heading "Risk Factors."

NOTE: POSIMIR^® and SABER^® are trademarks of DURECT Corporation.  Other referenced trademarks belong to their respective owners.  DUR-928 is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication. Full prescribing information for POSIMIR, including its Boxed Warning, can be found at www.posimir.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-fireside-chat-at-the-hc-wainwright-5th-annual-nash-investor-conference-301395086.html

SOURCE DURECT Corporation

FAQ

What is the date of DURECT Corporation's fireside chat at the H.C. Wainwright conference?

The fireside chat is scheduled for October 12, 2021.

Who are the key executives participating in the DURECT Corporation fireside chat?

Key executives include CEO James E. Brown and CFO Michael H. Arenberg.

What is DUR-928 and its significance for DURECT Corporation?

DUR-928 is DURECT's lead drug candidate in clinical development for alcohol-associated hepatitis and has FDA Fast Track Designation.

What conference is DURECT Corporation participating in?

DURECT Corporation is participating in the H.C. Wainwright 5th Annual NASH Investor Conference.

What is POSIMIR and its current status?

POSIMIR is a non-opioid analgesic that has been approved by the FDA.